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Both plaque macrophage infiltration [1] and 
calcification [2] are recently suggested character-
istics of plaque vulnerability in coronary lesions. 
Each of these two morphologic characteristics may 
foster the other [3, 4]. Thus, the aim herein, is to 
evaluate this interdependence using optical coher-
ence tomography (OCT), which, due to its supreme 
resolution, has the ability to detect both features. 
A recent study defined colocalization of macro-
phages and calcification (ColocCaMa) as a dis-
tance < 100 µm between plaque macrophages 
and calcification. In this work an association was 
described between ColocCaMa and the more 
heavily calcified, but also less advanced and more 
vulnerable coronary lesions [5]. An example of 
ColocCaMa is shown in Figure 1A. In the pres-
ent follow-up study, the aim was to investigate 
whether this more vulnerable plaque phenotype 
in the presence of ColoCaMa translates into more 
cardiovascular events.
One hundred and fifty five patients were pro-
spectively enrolled, who underwent percutaneous 
coronary intervention (PCI) of the target lesion due 
to stable angina (116, 74.8%) or acute coronary 
syndrome (ACS; 39, 25.2%) between 2012 and 2014 
at the University Hospital of the RWTH Aachen, 
Germany. Patients were enrolled consecutively on 
days in which the study team was available. Further 
inclusion criteria were the suitability of the coro-
nary target lesion for OCT analysis, as well as the 
presence of calcification within the target segment. 
A standardized follow-up was then performed with 
a median follow-up of 5.4 years (IQR 4.4–5.8). 
25 patients were lost to follow-up, thus resulting 
in 130 patients with complete information. Death 
from any cause, new onset of myocardial infarction 
(MI), as well as emergent coronary revasculariza-
tion and the composite endpoint of the three were 
noted. Written informed consent was obtained from 
all patients. The study was approved by the local 
ethics committee and conforms to the declaration 
of Helsinki. All statistical analyses were performed 
with SPSS (IBM Corp., Armonk, NY, USA).
Baseline age was 69.6 ± 8.4 years; 26 (20%) 
patients suffered an ACS at inclusion. Prevalence 
of cardiovascular risk factors was high: 63.1% 
presented with diabetes, 85.4% hypertension and 
62.3% hyperlipidemia. A thin-capped fibroatheroma 
was present in 34 (26.1%) patients, macrophage 
infiltration in 48 (36.9%) patients and ColocCaMa 
in 23 (17.6%) patients. Frequency of thin-capped 
fibroatheroma was similar in patients with and 
without ColocCaMa (28 [26.2%] vs. 6 [26.1%], 
p = 0.393). Inter- and intraobserver variability for 
the assessment of the presence of macrophages 
were 0.916 and 0.925, respectively.
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At follow-up, 29 (22.3%) deaths, 26 (20%) new 
MI and 43 (33.1%) emergent coronary revascular-
izations were registered. The composite endpoint 
was met by 65 (50%) patients. This high incidence 
of adverse cardiovascular events may be explained 
by the high cardiovascular risk profile of the en-
rolled population. No difference in the frequency 
of thin-capped fibroatheroma (20 [35.1%] vs. 
14 [28.6%], p = 0.617) was detected among pa-
tients with or without adverse outcome at follow-
up, whereas patients with adverse outcome showed 
more frequent plaque macrophage infiltration 
(32 [53.3%] vs. 20 [32.3%], p = 0.019). In contrast 
to a previous study [6], in-stent minimal lumen 
area < 4.5 mm2, narrowing of proximal or distal 
stent edges or distal dissection did not predict 
adverse outcome, probably due to the routine 
use of OCT-guided PCI-optimization. Using Cox-
regression analysis, patients with ColocCaMa 
showed a significantly higher incidence of the 
composite endpoint of death from any cause, MI 
and coronary revascularization (HR 1.83, 95% CI 
1.03–3.24, p = 0.039). In patients with ColocCaMa 
this increased risk for the composite endpoint is 
sustained over time and curves derived from Cox 
regression analysis are depicted in Figure 1B. 
Following adjustment for clinical presentation 
(ACS vs. stable angina), age, sex, glomerular filtra-
Figure 1. ColocCaMa in the coronary target/culprit lesion is associated with adverse cardiovascular outcome; 
A. A representative optical coherence tomography image of a ColocCaMa is shown; macrophage accumulation is 
marked with a white arrow, and calcification with a yellow border; B. The event-free curves derived from the Cox-
-regression show that in the presence of ColocCaMa (green line) in the target/culprit lesion, patients show a higher 
incidence of the composite endpoint of death from any cause, myocardial infarction and coronary revascularization; 
C. The forest-plot for single and composite endpoints is shown after adjustment for clinical presentation (acute coro-
nary syndrome vs. stable angina), age, sex, glomerular filtration rate and relevant cardiovascular risk factors (body 
mass index, active nicotine use, presence of diabetes mellitus, hypertension, hyperlipidemia).
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tion rate and relevant cardiovascular risk factors 
(body mass index, active nicotine use, presence of 
diabetes mellitus, hypertension, hyperlipidemia) 
ColocCaMa still represented a significant risk 
factor for the composite endpoint (HR 1.98, 95% 
CI 1.07–3.67, p = 0.030, Fig. 1C). Furthermore, 
ColocCaMa was associated with death from any 
cause (HR 2.69, 95% CI 1.01–7.30, p = 0.049) 
and MI (HR 2.91, 95% CI 1.04–8.15, p = 0.043), 
whereas emergent coronary revascularization (HR 
1.93, 95% CI 0.94–4.00, p = 0.075) did not reach 
significance in the adjusted model. Furthermore, 
in order to avoid any possible bias due to patients 
lost at follow-up, a multiple imputation analysis was 
performed, which confirmed the higher risk of the 
composite endpoint in patients with ColocCaMa 
(OR 1.78–1.82, p = 0.039–0.046).
The present group previously demonstrated 
that ColocCaMa is associated with a more vulner-
able plaque phenotype [5]. In this study it was dem-
onstrated that this translates into higher incidence 
of the composite endpoint of death from any cause, 
MI and coronary revascularization at follow-up. 
 Postinterventional OCT was performed in all 
patients, and relevant stent edge dissections or 
stent malappositions were treated immediately. 
Thus, it seems unlikely that the higher event 
rate in patients with ColocCaMa is caused by me-
chanical effects following coronary intervention. 
Furthermore, it has to be noticed that the survival 
curves progressively diverge over time suggesting 
an atherosclerosis-mediated effect. This is in line 
with the role of macrophages and microcalcifica-
tions as active players in atherogenesis and plaque 
destabilization. Even though stent implantation 
was performed in all the current patients, the data 
may be interpreted in light of the current concept 
of “vulnerable patient”, i.e. patients with a ten-
dency towards multifocal vulnerable lesions [7]. 
Specifically, previous OCT studies demonstrated 
more vulnerable lesions in non-culprit vessels of 
patients with ACS compared to stable coronary ar-
tery disease [1, 8]. In this scenario, ColocCaMa may 
be a marker of patient vulnerability, thus unmasking 
the higher risk of certain sub-populations. On the 
other hand, ColocCaMa could also be associated 
with an accelerated local neo-atherosclerosis fol-
lowing stent implantation, which may therefore lead 
to re-stenosis and eventually to adverse outcomes. 
However, as standardized follow-up coronary angi-
ographies were not performed in this study due to 
ethical reasons, it is still unclear if the composite 
endpoint is driven by a non-culprit lesion or culprit 
lesion stent failure due to ColocCaMa — this needs 
to be investigated in future studies.
Given that both plaque macrophages and mi-
crocalcifications increase plaque destabilization, 
it is tempting to speculate about a causal role of 
ColocCaMa in the genesis of plaque vulnerability 
and future cardiovascular events. However, due 
to the study design it remains unclear whether 
ColocCaMa is causally involved in plaque destabi-
lization or merely reflects a localized or systemic 
vulnerable coronary artery disease. In the present 
study, there was not sufficient information on 
target lesion revascularization during follow-up. 
Moreover, although the inter- and intraobserver 
variability in detecting macrophage infiltration is 
acceptable and a recent study using directional 
atherectomy showed good accuracy of accepted 
OCT-criteria [9] in detecting macrophages [10], the 
presence of ColocCaMa was not directly validated 
using histopathology in this study due to the study 
design. A promising tool for macrophage detection 
may be offered by computer-based reconstruc-
tions, however, they were not used in this project. 
Furthermore, the small number of patients did not 
allow drawing definite conclusions about a possible 
correlation of other features of plaque vulnerability 
with adverse outcome.
In summary, the present data suggests and 
may allow others to identify a subgroup of patients 
with high cardiovascular risk and  indicates Coloc-
CaMa to be a novel vulnerable plaque feature. 
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